7A9
7A9
规格:
货期:
编号:TS212789
品牌:Testobio
| 产品名称： | 7A9 |
|---|---|
| 商品货号： | TS212789 |
| Organism： | Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Cell Type： | hybridoma: B lymphocyte |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Applications： | The antibody binds to IL-1 activated human endothelial cells, but not to resting endothelial cells or IL-1 treated mononuclear leukocytes, fibroblasts or keratinocytes. |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Derivation： | Spleen cells were fused with mouse myeloma cells. |
| Genes Expressed： | immunoglobulin; monoclonal antibody; against interleukin 1 (IL-1) activated human endothelial cells |
| Cellular Products： | immunoglobulin; monoclonal antibody; against interleukin 1 (IL-1) activated human endothelial cells |
| Comments： | Animals were immunized with IL-1 activated human umbilical vein endothelial cells. Spleen cells were fused with mouse myeloma cells. The antibody binds to IL-1 activated human endothelial cells, but not to resting endothelial cells or IL-1 treated mononuclear leukocytes, fibroblasts or keratinocytes. It precipitates an antigen consisting of a 100000 dalton polypeptide (90000 daltons under reducing conditions). The antibody totally blocks binding of granulocytes and partially blocks monocyte binding to IL-1 stimulated endothelial cells. |
| Complete Growth Medium： | Culture Medium: RPMI medium 1640 with 0.016 mM thymidine, 0.1 mM hypoxanthine, 85%; fetal bovine serum, 15%. |
| Subculturing： | Medium Renewal: Every 2 to 3 days Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml. |
| Isotype： | IgG1 |
| Name of Depositor： | Otsuka Pharmaceuticals Co., Ltd. |
| Deposited As： | mouse (B cell); mouse (myeloma) |
| U.S. Patent Number： | |
| References： | Newman W, Wilson DO. Monoclonal antibodies directed to IL-1 activated endothelial cells and medicaments employing the monoclonal antibodies. US Patent 5,011,778 dated Apr 30 1991 |
首页 >
产品中心
>
微生物培养
>
菌株
>
null
>
7A9
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | 7A9 |
|---|---|
| 商品货号： | TS212789 |
| Organism： | Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Cell Type： | hybridoma: B lymphocyte |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Applications： | The antibody binds to IL-1 activated human endothelial cells, but not to resting endothelial cells or IL-1 treated mononuclear leukocytes, fibroblasts or keratinocytes. |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Derivation： | Spleen cells were fused with mouse myeloma cells. |
| Genes Expressed： | immunoglobulin; monoclonal antibody; against interleukin 1 (IL-1) activated human endothelial cells |
| Cellular Products： | immunoglobulin; monoclonal antibody; against interleukin 1 (IL-1) activated human endothelial cells |
| Comments： | Animals were immunized with IL-1 activated human umbilical vein endothelial cells. Spleen cells were fused with mouse myeloma cells. The antibody binds to IL-1 activated human endothelial cells, but not to resting endothelial cells or IL-1 treated mononuclear leukocytes, fibroblasts or keratinocytes. It precipitates an antigen consisting of a 100000 dalton polypeptide (90000 daltons under reducing conditions). The antibody totally blocks binding of granulocytes and partially blocks monocyte binding to IL-1 stimulated endothelial cells. |
| Complete Growth Medium： | Culture Medium: RPMI medium 1640 with 0.016 mM thymidine, 0.1 mM hypoxanthine, 85%; fetal bovine serum, 15%. |
| Subculturing： | Medium Renewal: Every 2 to 3 days Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml. |
| Isotype： | IgG1 |
| Name of Depositor： | Otsuka Pharmaceuticals Co., Ltd. |
| Deposited As： | mouse (B cell); mouse (myeloma) |
| U.S. Patent Number： | |
| References： | Newman W, Wilson DO. Monoclonal antibodies directed to IL-1 activated endothelial cells and medicaments employing the monoclonal antibodies. US Patent 5,011,778 dated Apr 30 1991 |
